Delayed
OTC Markets
02:57:07 2024-07-05 pm EDT
|
5-day change
|
1st Jan Change
|
0.06
USD
|
+23.08%
|
|
+22.95%
|
-45.45%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
14.51
|
31.15
|
1.457
|
6.087
|
Enterprise Value (EV)
1 |
15.02
|
32.19
|
2.826
|
7.478
|
P/E ratio
|
-17.5
x
|
-84.3
x
|
-1.97
x
|
-12.6
x
|
Yield
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
2,067,715,690
x
|
45,744,834,068
x
|
2,574,710,247
x
|
40,583,040,000
x
|
EV / Revenue
|
2,141,015,534
x
|
47,269,734,214
x
|
4,992,369,258
x
|
49,855,966,667
x
|
EV / EBITDA
|
-19,254,092
x
|
-62,332,991
x
|
-5,447,411
x
|
-30,279,232
x
|
EV / FCF
|
-34,244,185
x
|
-59,878,180
x
|
-51,931,210
x
|
67,612,923
x
|
FCF Yield
|
-0%
|
-0%
|
-0%
|
0%
|
Price to Book
|
-25.5
x
|
-33.3
x
|
-0.89
x
|
-3.19
x
|
Nbr of stocks (in thousands)
|
50,782
|
51,920
|
52,420
|
55,341
|
Reference price
2 |
0.2857
|
0.6000
|
0.0278
|
0.1100
|
Announcement Date
|
4/15/21
|
4/29/22
|
4/17/23
|
4/16/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
0.007017
|
0.000681
|
0.000566
|
0.00015
|
EBITDA
|
-
|
-0.2287
|
-0.7803
|
-0.5164
|
-0.5187
|
-0.247
|
EBIT
1 |
-0.095
|
-0.2292
|
-0.7853
|
-0.5215
|
-0.5229
|
-0.2509
|
Operating Margin
|
-
|
-
|
-11,191.34%
|
-76,571.37%
|
-92,382.16%
|
-167,239.33%
|
Earnings before Tax (EBT)
1 |
-0.095
|
-0.2524
|
-0.8163
|
-0.367
|
-0.7347
|
-0.4777
|
Net income
1 |
-0.095
|
-0.2524
|
-0.8163
|
-0.367
|
-0.7347
|
-0.4777
|
Net margin
|
-
|
-
|
-11,632.62%
|
-53,894.57%
|
-129,812.19%
|
-318,489.33%
|
EPS
2 |
-0.001869
|
-0.004925
|
-0.0163
|
-0.007115
|
-0.0141
|
-0.008716
|
Free Cash Flow
|
-
|
-0.1801
|
-0.4387
|
-0.5376
|
-0.0544
|
0.1106
|
FCF margin
|
-
|
-
|
-6,252.2%
|
-78,943.17%
|
-9,613.43%
|
73,737.33%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
8/29/19
|
5/29/20
|
4/15/21
|
4/29/22
|
4/17/23
|
4/16/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
0.1
|
0.23
|
0.51
|
1.04
|
1.37
|
1.39
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-1.013
x
|
-0.6592
x
|
-2.011
x
|
-2.638
x
|
-5.632
x
|
Free Cash Flow
|
-
|
-0.18
|
-0.44
|
-0.54
|
-0.05
|
0.11
|
ROE (net income / shareholders' equity)
|
107%
|
148%
|
206%
|
48.8%
|
57%
|
26.7%
|
ROA (Net income/ Total Assets)
|
-
|
-125%
|
-232%
|
-101%
|
-100%
|
-69.7%
|
Assets
1 |
-
|
0.2021
|
0.3525
|
0.364
|
0.7346
|
0.6859
|
Book Value Per Share
2 |
-0
|
-0
|
-0.0100
|
-0.0200
|
-0.0300
|
-0.0300
|
Cash Flow per Share
2 |
0
|
0
|
0
|
0
|
0
|
0
|
Capex
|
-
|
0
|
0.04
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
559.74%
|
-
|
-
|
-
|
Announcement Date
|
8/29/19
|
5/29/20
|
4/15/21
|
4/29/22
|
4/17/23
|
4/16/24
|
|
1st Jan change
|
Capi.
|
---|
| -45.45% | 3.86M | | +12.92% | 5B | | -32.29% | 3.52B | | -4.28% | 3.11B | | -24.21% | 2.65B | | -8.82% | 2.31B | | +39.33% | 1.86B | | +40.81% | 1.5B | | -14.27% | 1.41B | | +41.90% | 1.37B |
Alternative Medicine
|